HEK293-CD20

305987

GENERAL INFORMATION

Description

Disclaimer: The prices displayed for cell lines are exclusively for academic/not-for-profit customers. For commercial entitites the price is approximately €6,250.
If you represent a commercial entity or are unsure which category applies, please
contact us.
HEK293-CD20 cells are human embryonic kidney 293 (HEK293) cells engineered to stably express human CD20 (MS4A1), a non-glycosylated transmembrane phosphoprotein primarily expressed on B lymphocytes. CD20 is involved in regulation of B-cell activation, proliferation, differentiation, and calcium signaling, and serves as one of the most extensively validated therapeutic targets in hematologic malignancies and autoimmune diseases. Stable HEK293-CD20 models provide controlled and reproducible surface expression of the antigen, enabling detailed characterization of CD20-targeted therapeutics and immune-mediated mechanisms.
HEK293-CD20 cells are widely used in immuno-oncology and biologics development for evaluation of monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and engineered immune cell therapies targeting CD20. These cells support quantitative analysis of antibody binding affinity, epitope specificity, receptor occupancy, internalization dynamics, and Fc-mediated immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). They are also commonly applied in flow cytometry assay development, potency testing, reporter bioassays, and high-throughput therapeutic screening workflows. Because HEK293 cells support efficient recombinant protein expression and robust cell growth, they provide a reliable and scalable platform for standardized assay generation and target validation studies.

Tissue	Fetal Kidney
Disease	Transformed/immortalized; non-tumorigenic (HEK293 background)

Applications

CD20-targeted antibody and bispecific antibody development; CAR-T cell therapy; ADCC/CDC assays; flow cytometry; biologics potency testing; B-cell antigen research

CLASSIFICATION

Organism	Human
Sex	Female
Growth properties	Adherent
GMO status	GMO-S1

GMO status details

GMO-S1: This HEK293 cell line contains a CD20 (MS4A1) expression construct for therapeutic antibody and immune effector function studies. This classification applies only within Germany and may differ elsewhere.

Biosafety level	1

CHARACTERISTICS

Morphology	Epithelial-like
Cell type	Epithelial cells
Doubling time	approx. 24-36 hours

Cytion GmbH
Nikola-Tesla-Str. 3
69124 Heidelberg
Tel: +49 (0)6221 405780
info@cytion.com
cytion.com

Registered office Heidelberg
VAT ID: DE283292917
Local court Mannheim - HRB 714394
CEO / Geschäftsführer: Jonathan Steubing

Banking information
Sparkasse Heidelberg
IBAN: DE35 6725 0020 0009 2076 86
BIC: SOLADES1HDB

IDENTIFIERS

Citation

HEK293-CD20 (Cytion catalog number 305987)

NCBI TaxID	9606
Cellosaurus	CVCL_A8V4

EXPRESSION AND SUSCEPTIBILITY

Receptors expressed

CD20

HANDLING AND CULTURE

Culture medium

RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a)

Incubation atmosphere	37°C, 5% CO_2, humidified atmosphere.

Supplements

Supplement the medium with 10% FBS, 1 mM sodium pyruvate, 10 mM HEPES, 1% NEAA. Add Geneticin (G418-Sulfat) to achieve a final concentration of 1 mg/mL.

Dissociation reagent	Trypsin-EDTA

Subculturing

For routine adherent cell culture: Aspirate the old culture medium from the adherent cells, and wash them with PBS to remove any remaining medium. After aspirating the PBS, add the appropriate volume of Trypsin/EDTA solution based on the culture vessel size (e.g., 1 ml for a T25 flask, 3 ml for a T75 flask) and incubate at room temperature or 37°C until the cells detach (5-10 minutes). Monitor detachment under a microscope, and gently tap the vessel if necessary to release the cells. Once detached, add complete medium to inactivate the Trypsin/EDTA, gently resuspend the cells, and transfer an aliquot of the cell suspension into a new culture vessel containing fresh medium. Place the vessel in an incubator set to 37°C with 5% CO_2, and change the medium every 2-3 days.

Split ratio	1 to 5
Seeding density	2 to 4 x 10^4 cells/cm^2
Fluid renewal	2 to 3 times per week
Post-thaw recovery	After thawing, split the cells at a ratio of 1:2 to 1:3 in T25 flasks and allow the cells to recover from the freezing process and to adhere (for adherent cultures) for at least 24 hours.

Thawing and culturing

Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.
Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.
For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.
Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.
Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.
Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.
Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.
Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

QUALITY CONTROL AND CRYOPRESERVATION

Sterility

Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods.
To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

Freeze medium	As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.

Storage conditions

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Shipping conditions

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

DONOR

Donor age	Fetus

LEGAL AND SAFETY

Safety precautions

When planning to store a cryovial in liquid nitrogen for future thawing, it is mandatory to adhere to stringent safety measures. Appropriate protective gloves and clothing are essential, and the use of a face mask or safety goggles is required during the transfer of frozen samples to or from the liquid nitrogen tank. This is to mitigate the risk of injury from potential cryovial explosions upon removal, which can result in the projection of sharp fragments.

Disclaimer

Our cells are provided for in vitro laboratory research purposes exclusively and are not intended for clinical or diagnostic use, nor are they to be administered to humans or used for veterinary purposes. Users must adhere to all applicable guidelines and regulations for the handling and use of these cells in a research setting.

Warranty

At Cytion, we stand behind the quality and viability of our products.
We guarantee that our cells will be viable at the start of culture for
60 days after shipment from our facilities.
We assure that all materials conform to the specifications described in the
Certificate of Analysis and/or Product Sheet.
For full details, please refer to our
Warranty Statement.

Third-party agreements apply	Yes